Sort   by:  
 Page size 
MetabolomicsAlterations in CSF Urea Occur in Late Manifest Stage Huntington Disease
Not available
ORGANISM(S): Homo sapiens 
ST002442 | MetabolomicsWorkbench
ProteomicsProteome profiling of an isogenic CAG allelic panel of Huntington disease hESCs and NPCs
Whole proteome profiling and quantification was performed on an isogenic Huntington disease (IsoHD) human embryonic stem cell (hESC) allelic panel. The IsoHD hESCs harbour 30, 45, 65 and 81 CAG repeats in the first exon of HTT. Whole proteome quantification was also performed on neural progenitor ce...
ORGANISM(S): Homo Sapiens (human) 
2019-02-14 | PXD006585 | JPOST Repository
MetabolomicsAlterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington’s disease subjects
Huntington's disease (HD) is a severe neurological disease leading to psychiatric symptoms, motor impairment and cognitive decline. The disease is caused by a CAG expansion in the huntingtin (HTT) gene, but how this translates into the clinical phenotype of HD remains elusive. Using liquid chromatog...
2019-06-21 | MTBLS749 | MetaboLights
TranscriptomicsStriatum of Huntington's disease model mice [Affymetrix data]
Evaluation of transcriptional changes in the striatum may be an effective approach to understanding the natural history of changes in expression contributing to the pathogenesis of Huntington disease (HD). We have performed genome-wide expression profiling of the YAC128 transgenic mouse model of HD ...
ORGANISM(S): Mus musculus 
2010-02-21 | E-GEOD-18551 | biostudies-arrayexpress
UnknownLonger CAG repeat length is associated with shorter survival after disease onset in Huntington disease.
Not available
S-EPMC8764269 | biostudies-literature
GenomicsTargeting H3K4 methylation as a therapeutic strategy for Huntington's disease (ChIP-seq)
Transcriptional dysregulation is an early feature of Huntington's disease (HD). We observed gene-specific changes in H3K4me3 at transcriptionally repressed promoters in R6/2 mouse and human HD brain. Genome-wide analysis showed a novel chromatin signature for this mark. Reducing the levels of the H3...
ORGANISM(S): Mus musculus 
2013-07-18 | E-GEOD-48960 | biostudies-arrayexpress
TranscriptomicsTargeting H3K4 methylation as a therapeutic strategy for Huntington's disease (RNA-seq)
Transcriptional dysregulation is an early feature of Huntington's disease (HD). We observed gene-specific changes in H3K4me3 at transcriptionally repressed promoters in R6/2 mouse and human HD brain. Genome-wide analysis showed a novel chromatin signature for this mark. Reducing the levels of the H3...
ORGANISM(S): Mus musculus 
2013-07-18 | E-GEOD-48962 | biostudies-arrayexpress
TranscriptomicsThe transcriptional modulator H2AFY marks Huntington's disease activity in men and mice
To accelerate the development of disease-modifying therapeutics for Huntington’s disease (HD), a dynamic biomarker of disease activity and treatment response is critically needed. Venous cellular whole blood from 8 patients with Huntington's disease (HD) and 6 control subjects were collected in PAXg...
ORGANISM(S): Homo sapiens 
2011-09-01 | E-GEOD-24250 | biostudies-arrayexpress
GenomicsRARb and Huntington Disease
RARb and Huntington Disease
PRJNA1129147 | ENA
TranscriptomicsHuntington disease protein accelerates tumour development and metastasis
Huntington disease is a severe neurological disorder caused by an abnormal polyglutamine expansion in the N-terminal of the huntingtin protein. Here we show that breast tumours appear earlier when mutant huntingtin is expressed in an activated polyomavirus middle T antigen (PyVT) mouse breast cancer...
ORGANISM(S): Mus musculus 
2014-04-14 | E-GEOD-28685 | biostudies-arrayexpress
Sort   by:  
 Page size